Sarcoidosis Pipeline Analysis report covers drugs of 9 companies currently in different phases of development. Sarcoidosis is a rare inflammatory condition or disease which results in the formation of granulomas and causes organ inflammation. The disease is caused due to the body’s immune system responding to the foreign substances and they usually affect skin and lungs. Symptoms include red bumps on the skin, persistent cough and shortness of breath. As granulomas build up in the organ it may affect the functioning of the organ.
The report provides Sarcoidosis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Araim Pharmaceuticals, Inc., Novartis AG and Reata Pharmaceuticals, Inc among others.
Scope:
The report provides Sarcoidosis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Araim Pharmaceuticals, Inc., Novartis AG and Reata Pharmaceuticals, Inc among others.
Scope:
- By Company
- By Phase
- By Molecule Type
- By Region
- By Route of Administration
Table of Contents
1. Introduction1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
- Drug Name
- Generic Name
- Synonyms
- Company
- Collaborator
- Route of administration
- Target
- Mechanism of Action
- Technology
- Molecule type
- CAS Number
- Weight
- Chemical Formula
- IUPAC name
- ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. Araim Pharmaceuticals, Inc.
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. Novartis AG
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. CELGENE CORPORATION
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. Reata Pharmaceuticals, Inc
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. BELLUS HEALTH
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. RELIEF THERAPEUTICS Holding SA
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. OncoArendi Therapeutics
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. Bellerophon Therapeutics
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. Gotham Biopharmaceuticals, Inc.
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
List of Tables
List of Figures
Companies Mentioned
- Araim Pharmaceuticals, Inc.
- Novartis AG
- CELGENE CORPORATION
- Reata Pharmaceuticals, Inc
- BELLUS HEALTH
- RELIEF THERAPEUTICS Holding SA
- OncoArendi Therapeutics
- Bellerophon Therapeutics
- Gotham Biopharmaceuticals, Inc
Methodology
LOADING...
